Immunomodulators, Immunostimulants, and Immunotherapies in Small Animal Veterinary Medicine

Veterinary Clinics of North America - Small Animal Practice

Volumn 40, Issue 3, 2010, Pages 473-483

  Thacker, Eileen L ^a  

^a AGRICULTURAL RESEARCH SERVICE   (United States)

Author keywords

Immune system; Immunomodulators; Immunotherapies; Small animals

Indexed keywords

ACEMANNAN; ACETYLSALICYLIC ACID; ASTRAGALUS MEMBRANACEUS EXTRACT; AZATHIOPRINE; BACTERIUM LYSATE; CARPROFEN; CORTICOSTEROID; CPG OLIGODEOXYNUCLEOTIDE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ECHINACEA EXTRACT; ELEUTHEROCOCCUS SENTICOSUS EXTRACT; FLUNIXIN MEGLUMINE; GAMMA INTERFERON; GANODERMA LUCIDUM EXTRACT; GINSENG EXTRACT; IMMUNOMODULATING AGENT; IMMUNOSTIMULATING AGENT; INTERLEUKIN 2; LENTINULA EDODES EXTRACT; LEVAMISOLE; PHENYLBUTAZONE; PREDNISOLONE; PREDNISONE; SAPONIN; STAPHAGE LYSATE; T LYMPHOCYTE IMMUNE MODULATOR; TACROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE; WITHANIA SOMNIFERA EXTRACT;

ADRENAL INSUFFICIENCY; ALLERGY; ANEMIA; ANIMAL CARE; ANOREXIA; ANUS FISTULA; ARTHRALGIA; ASTHMA; ATOPIC DERMATITIS; AUTOIMMUNE DISEASE; BONE MARROW SUPPRESSION; CALLUS; COLITIS; DERMATITIS; DIARRHEA; DISCOID LUPUS ERYTHEMATOSUS; ENTERITIS; EOSINOPHILIC GRANULOMA; FELINE LEUKEMIA; FELINE LEUKEMIA VIRUS; GASTROINTESTINAL TOXICITY; GLOMERULONEPHRITIS; HELMINTHIASIS; HEMOLYTIC ANEMIA; HYPERADRENOCORTICISM; IMMUNE DEFICIENCY; IMMUNOMODULATION; IMMUNOPATHOLOGY; IMMUNOSTIMULATION; IMMUNOTHERAPY; KERATOCONJUNCTIVITIS SICCA; LUPUS ERYTHEMATOSUS; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MYASTHENIA GRAVIS; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; PEMPHIGUS; PERITONITIS; POLYARTHRITIS; POLYNEUROPATHY; PYODERMA; REVIEW; SKIN DISEASE; STOMACH PERFORATION; STOMACH ULCER; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; THROMBOCYTOPENIA; VETERINARY MEDICINE; VOMITING;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANIMALS, DOMESTIC; IMMUNE SYSTEM DISEASES; IMMUNOMODULATION; IMMUNOTHERAPY;

ANIMALIA;

EID: 77952778255     PISSN: 01955616     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cvsm.2010.01.004     Document Type: Review

References (46)

1. Kampa M., Castanas E. Membrane steroid receptor signaling in normal and neoplastic cells. Mol Cell Endocrinol 2006, 246:76.
2. Galon J., Franchimont D., Hiroi N., et al. Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells. FASEB J 2002, 16:61.
3. Rhen T., Cidlowski J.A. Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. N Engl J Med 2005, 353:1711.
4. Dannenberg A.M. The antiinflammatory effects of glucocorticosteroids. A brief review of the literature. Inflammation 1979, 3:329.
5. Rinkardt N.E., Kruth S.A., Kaushik A. The effects of prednisone and azathioprine on circulating immunoglobulin levels and lymphocyte subpopulations in normal dogs. Can J Vet Res 1999, 63:18.
6. Olivry T., Mueller R.S. Evidence-based veterinary dermatology: a systematic review of the pharmacotherapy of canine atopic dermatitis. Vet Dermatol 2003, 14:121.
7. Mathews K.A. Nonsteroidal anti-inflammatory analgesics in pain management in dogs and cats. Can Vet J 1996, 37:539.
8. Sanderson R.O., Beata C., Flipo R.M., et al. Systematic review of the management of canine osteoarthritis. Vet Rec 2009, 164:418.
9. Clark T.P. The clinical pharmacology of cyclooxygenase-2-selective and dual inhibitors. Vet Clin North Am Small Anim Pract 2006, 36:1061.
10. Narita T., Sato R., Motoishi K., et al. The interaction between orally administered non-steroidal anti-inflammatory drugs and prednisolone in healthy dogs. J Vet Med Sci 2007, 69:353.
11. Streppa H.K., Jones C.J., Budsberg S.C. Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs in canine blood. Am J Vet Res 2002, 63:91.
12. Boonsoda S., Wanikiat P. Possible role of cyclooxygenase-2 inhibitors as anticancer agents. Vet Rec 2008, 162:159.
13. Moore C.P. Immunomodulating agents. Vet Clin North Am Small Anim Pract 2004, 34:725.
14. Bierer B.E., Mattila P.S., Standaert R.F., et al. Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin. Proc Natl Acad Sci U S A 1990, 87:9231.
15. Steffan J., Favrot C., Mueller R. A systematic review and meta-analysis of the efficacy and safety of cyclosporin for the treatment of atopic dermatitis in dogs. Vet Dermatol 2006, 17:3.
16. Steffan J., Strehlau G., Maurer M., et al. Cyclosporin A pharmacokinetics and efficacy in the treatment of atopic dermatitis in dogs. J Vet Pharmacol Ther 2004, 27:231.
17. Wisselink M.A., Willemse T. The efficacy of cyclosporine A in cats with presumed atopic dermatitis: a double blind, randomised prednisolone-controlled study. Vet J 2009, 180:55.
18. Murphy K., Travers P., Walport M. Janeway's Immunobiology 2008, Garland Science, Taylor & Francis Group, LLC, New York.
19. Day M.J. Clinical immunology of the dog and cat 1999, Iowa State University Press, Ames (IA).
20. Radowicz S.N., Power H.T. Long-term use of cyclosporine in the treatment of canine atopic dermatitis. Vet Dermatol 2005, 16:81.
21. Moore C.P. Ocular therapeutics. Vet Clin North Am Small Anim Pract 2004, 34:XI.
22. Mortola E., Endo Y., Ohno K., et al. The use of two immunosuppressive drugs, cyclosporin A and tacrolimus, to inhibit virus replication and apoptosis in cells infected with feline immunodeficiency virus. Vet Res Commun 1998, 22:553.
23. Rodriguez D.B., Mackin A., Easley R., et al. Relationship between red blood cell thiopurine methyltransferase activity and myelotoxicity in dogs receiving azathioprine. J Vet Intern Med 2004, 18:339.
24. Cave T.A., Norman P., Mellor D. Cytotoxic drug use in treatment of dogs and cats with cancer by UK veterinary practices (2003 to 2004). J Small Anim Pract 2007, 48:371.
25. Goggs R., Boag A.K., Chan D.L. Concurrent immune-mediated haemolytic anaemia and severe thrombocytopenia in 21 dogs. Vet Rec 2008, 163:323.
26. Piek C.J., Junius G., Dekker A., et al. Idiopathic immune-mediated hemolytic anemia: treatment outcome and prognostic factors in 149 dogs. J Vet Intern Med 2008, 22:366.
27. Gingerich D.A. Lymphocyte T-Cell immunomodulator (LTCI): review of the immunopharmacology of a new veterinary biologic. J Appl Res Vet Med 2008, 6:61.
28. de Mari K., Maynard L., Sanquer A., et al. Therapeutic effects of recombinant feline interferon-omega on feline leukemia virus (FeLV)-infected and FeLV/feline immunodeficiency virus (FIV)-coinfected symptomatic cats. J Vet Intern Med 2004, 18:477.
29. Zhang W., Du X., Zhao G., et al. Levamisole is a potential facilitator for the activation of Th1 responses of the subunit HBV vaccination. Vaccine 2009, 27:4938.
30. Wynn S.G., Fougere B. Veterinary herbal medicine: a systems-based approach. Veterinary herbal medicine 2007, 291. Mosby/Elsevier, New York. S.G. Wynn, B. Fougere (Eds.).
31. Sullivan A.M., Laba J.G., Moore J.A., et al. Echinacea-induced macrophage activation. Immunopharmacol Immunotoxicol 2008, 30:553.
32. Gryzlak B.M., Wallace R.B., Zimmerman M.B., et al. National surveillance of herbal dietary supplement exposures: the poison control center experience. Pharmacoepidemiol Drug Saf 2007, 16:947.
33. Klaschik S., Tross D., Shirota H., et al. Short- and long-term changes in gene expression mediated by the activation of TLR9. Mol Immunol December 17, 2009, [Online].
34. Wernette C.M., Smith B.F., Barksdale Z.L., et al. CpG oligodeoxynucleotides stimulate canine and feline immune cell proliferation. Vet Immunol Immunopathol 2002, 84:223.
35. Hayashi M., Satou E., Ueki R., et al. Resistance to influenza A virus infection by antigen-conjugated CpG oligonucleotides, a novel antigen-specific immunomodulator. Biochem Biophys Res Commun 2005, 329:230.
36. Reinero C.R., Cohn L.A., Delgado C., et al. Adjuvanted rush immunotherapy using CpG oligodeoxynucleotides in experimental feline allergic asthma. Vet Immunol Immunopathol 2008, 121:241.
37. DeBoer D.J., Moriello K.A., Thomas C.B., et al. Evaluation of a commercial staphylococcal bacteria for management of idiopathic recurrent superficial pyoderma in dogs. Am J Vet Res 1990, 51:636.
38. de Mari K., Maynard L., Eun H.M., et al. Treatment of canine parvoviral enteritis with interferon-omega in a placebo-controlled field trial. Vet Rec 2003, 152:105.
39. Kuwabara M., Nariai Y., Horiuchi Y., et al. Immunological effects of recombinant feline interferon-omega (KT-80) administration in the dog. Microbiol Immunol 2006, 50:637.
40. Nagashima N., Hisasue M., Nishigaki K., et al. In vitro selective suppression of feline myeloid colony formation is attributable to molecularly cloned strain of feline leukemia virus with unique long terminal repeat. Res Vet Sci 2005, 78:151.
41. Veir J.K., Lappin M.R., Dow S.W. Evaluation of a novel immunotherapy for treatment of chronic rhinitis in cats. J Feline Med Surg 2006, 8:400.
42. Talmadge J., Chavez J., Jacobs L., et al. Fractionation of Aloe vera L. inner gel, purification and molecular profiling of activity. Int Immunopharmacol 2004, 4:1757.
43. Harris C., Pierce K., King G., et al. Efficacy of acemannan in treatment of canine and feline spontaneous neoplasms. Mol Biother 1991, 3:207.
44. Fogleman R.W., Chapdelaine J.M., Carpenter R.H., et al. Toxicologic evaluation of injectable acemannan in the mouse, rat and dog. Vet Hum Toxicol 1992, 34:201.
45. Jahnke A., Hirschberger J., Fischer C., et al. Intra-tumoral gene delivery of feIL-2, feIFN-gamma and feGM-CSF using magnetofection as a neoadjuvant treatment option for feline fibrosarcomas: a phase-I study. J Vet Med A Physiol Pathol Clin Med 2007, 54:599.
46. von Euler H., Sadeghi A., Carlsson B., et al. Efficient adenovector CD40 ligand immunotherapy of canine malignant melanoma. J Immunother 2008, 31:377.